Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma

International Journal of Pharmaceutics

Volumn 381, Issue 2, 2009, Pages 122-129

  Oyarzun Ampuero, F A ^a   Brea, J ^b   Loza, M I ^b   Torres, D ^a   Alonso, M J ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Faculty of Pharmacy   (Spain)

Author keywords

Asthma; Chitosan; Heparin; Histamine; Hyaluronic acid; Nanoparticles

Indexed keywords

CHITOSAN; HEPARIN; HISTAMINE; HYALURONIC ACID; LOW MOLECULAR WEIGHT HEPARIN; NANOCARRIER; PHOSPHATE BUFFERED SALINE;

ANIMAL CELL; ARTICLE; ASTHMA; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; EX VIVO STUDY; FEMALE; GELATION; HISTAMINE RELEASE; INCUBATION TIME; INHIBITION KINETICS; INTERNALIZATION; MAST CELL; MAST CELL DEGRANULATION; NONHUMAN; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; ZETA POTENTIAL;

ALGORITHMS; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; CELL DEGRANULATION; CELL SURVIVAL; CHITOSAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; ENDOCYTOSIS; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HISTAMINE RELEASE; HYALURONIC ACID; INHIBITORY CONCENTRATION 50; MAST CELLS; NANOPARTICLES; P-METHOXY-N-METHYLPHENETHYLAMINE; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 70349281456     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.04.009     Document Type: Article

References (28)

1. Ahmed T., Ungo J., Zhou M., and Campo C. Inhibition of allergic late airway responses by inhaled heparin-derived oligosaccharides. J. Appl. Physiol. 88 (2000) 1721-1729
2. Aspden T.J., Mason J.D., Jones N.S., Lowe J., Skaugrud O., and Illum L. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J. Pharm. Sci. 86 (1997) 509-513
3. Buceta M., Dominguez E., Castro M., Brea J., Alvarez D., Barcala J., Valdes L., Alvarez-Calderon P., Dominguez F., Vidal B., Diaz J.L., Miralpeix M., Beleta J., Cadavid M.I., and Loza M.I. A new chemical tool (C0036E08) supports the role of adenosine A(2B) receptors in mediating human mast cell activation. Biochem. Pharmacol. 76 (2008) 912-921
4. Calvo P., Remuñan-Lopez C., Vila-Jato J.L., and Alonso M.J. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Polymer Sci. 63 (1997) 125-132
5. Campo C., Molinari J.F., Ungo J., and Ahmed T. Molecular-weight-dependent effects of nonanticoagulant heparins on allergic airway responses. J. Appl. Physiol. 86 (1999) 549-557
6. De Campos A.M., Diebold Y., Carvalho E.L., Sanchez A., and Alonso M.J. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm. Res. 21 (2004) 803-810
7. De la Fuente M., Seijo B., and Alonso M.J. Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Ther. 15 (2008) 668-676
8. De la Fuente M., Seijo B., and Alonso M.J. Novel hyaluronan-based nanocarriers for transmucosal delivery of macromolecules. Macromol. Biosci. 8 (2008) 441-450
9. Garcia-Fuentes M., Prego C., Torres D., and Alonso M.J. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur. J. Pharm. Sci. 25 (2005) 133-143
10. Green W.F., Konnaris K., and Woolcock A.J. Effect of salbutamol, fenoterol, and sodium cromoglicate on the release of heparin from sensitized human lung fragments challenged with Dermatophagoides pteronyssinus allergen. Am. J. Respir. Cell Mol. Biol. 8 (1993) 518-521
11. Halayko A.J., Recto E., and Sthepens N.L. Characterization of molecular determinants of smooth muscle cells heterogeneity. Can. J. Physiol. Pharmacol. 75 (1997) 917-919
12. Johnson P.R., Armour C.L., Carey D., and Black J.L. Heparin and PGE2 inhibit DNA synthesis in human airway smooth muscle cells in culture. Am. J. Physiol. 269 (1995) L514-L519
13. Kanabar V., Hirst S.J., ÓConnor B.J., and Page C.P. Some structural determinants of the antiproproliferative effect of heparin-like molecules on human airway smooth muscle. Br. J. Pharmacol. 146 (2005) 370-377
14. Kilfeather S.A., Tagoe S., Perez A.C., Okona-Mensa K., Matin R., and Page C.P. Inhibition of serum-induced proliferation of bovine tracheal smooth muscle cells in culture by heparin and related glycosaminoglycans. Br. J. Pharmacol. 114 (1995) 1442-1446
15. Köping-Höggård M., Sanchez A., and Alonso M.J. Nanoparticles as carriers for nasal vaccine delivery. Exp. Rev. Vaccines 4 (2005) 185-196
16. Lago J., Alfonso A., Vieytes M.R., and Botana L.M. Ouabain-induced enhancement of rat mast cells response. Modulation by protein phosphorylation and intracellular pH. Cell Signal 13 (2001) 515-524
17. Lim S.T., Martin G.P., Berry D.J., and Brown M.B. Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan. J. Control. Rel. 66 (2000) 281-292
18. Lopez-Leon T., Carvalho E.L., Seijo B., Ortega-Vinuesa J.L., and Bastos-Gonzalez D. Physicochemical characterization of chitosan nanoparticles: electrokinetic and stability behavior. J. Colloid Interface Sci. 283 (2005) 344-351
19. Martinez-Salas J., Mendelssohn R., Abraham W.M., Hsiao B., and Ahmed T. Inhibition of allergic airway responses by inhaled low-molecular-weight heparins: molecular-weight dependence. J. Appl. Physiol. 84 (1998) 222-228
20. Molinari J.F., Campo C., Shahida S., and Ahmed T. Inhibition of antigen-induced airway hyperresponsiveness by ultralow molecular-weight heparin. Am. J. Respir. Crit. Care Med. 157 (1998) 887-893
21. Niven A.S., and Argyros G. Alternate treatments in asthma. Chest 123 (2003) 1254-1265
22. Ortner M.J., and Chignell C.F. The effect of concentration on the binding of compound 48/80 to rat mast cells: a fluorescence microscopy study. Immunopharmacology 3 (1981) 187-191
23. Page C.P. One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta 2-agonist. Lancet 337 (1991) 717-720
24. Page S., Ammit A.J., Black J.L., and Armour C.L. Human mast cell and airway smooth muscle cell interactions: implications for asthma. Am. J. Physiol. Lung Cell. Mol. Physiol. 281 (2001) L1313-L1323
25. Prego C., García M., Torres D., and Alonso M.J. Transmucosal macromolecular drug delivery. J. Control Release 101 (2005) 151-162
26. Prichtard K., Lansley A.B., Martin G.P., Helliwell M., Marriot C., and Benedetti L.M. Evaluation of the bioadhesive properties of hyaluronan derivates: detachment weight and mucocilliary transport studies. Int. J. Pharm. 129 (1996) 137-145
27. Robinson D.S. The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle?. J. Allergy Clin. Immunol. 114 (2004) 58-65
28. Wong W.S., and Koh D.S. Advances in immunopharmacology of asthma. Biochem. Pharmacol. 59 (2000) 1323-1335